Drug Profile


Alternative Names: PGL-3; PGL-3001

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer PregLem
  • Class Infertility therapies; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 11 Oct 2010 Phase-II development is ongoing in Switzerland
  • 07 Oct 2010 PregLem has been acquired by Gedeon Richter
  • 27 Jun 2007 Phase-II clinical trials in Female infertility in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top